drugset / Trial / NCT02891954

Genetics of Response to Canagliflozin

NCT02891954

NaSingle-groupOpen-labelBasic science

Summary

Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin. A genome-wide association study (GWAS) will be conducted to search for genetic variants that are associated with each of the pharmacodynamic responses to canagliflozin.

Timeline

Start
2016-09
Primary completion
2023-09-25
Completion
2026-12-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg